Atrial Fibrillation (AF) is one of the most frequent arrhythmias, especially in elderly patients. Cardiac overload increases the incidence of AF. Clinical presentation of atrial fibrillation can occur as nonsustained paroxysms, persistent episodes and in chronic-permanent form. The physio-pathological mechanisms are:
to maintain a patient in sinus rhythm is more difficult when AF persists for longer [Van Gelder et al. 1991; Suttorp et al. 1990; Kopecky et al. 1987; Gold et al. 1986; Morris Jr et al. 1966 ]. This may be due to the evolution of an underlying pathology and/or due to AF itself inducing electrophysiological and structural changes, thereby facilitating the onset and persistence of AF, with these changes being known as 'remodeling.' This is in fact "arrythmogenic' remodeling because it promotes the occurrence of arrhythmias, which can also occur as:
(1) "Electrical": changes that primarily affect the electrical activity of the isolated myocyte or groups of them: alterations of ionic channels and cellular metabolism, with final changes in automatism, refractoriness, and myocardial conduction velocity.
(2) "Structural": changes in micro-and macro-structures.
Allessie's work on a goat model with rapid and sustained atrial stimulation -up to four weeks - [Ausma et al. 2003; Maurits et al. 1997 Maurits et al. , 1995 showed the changes induced by sustained tachycardia, with paroxistic AF being induced by this stimulation. After some days, AF was easier to induce, maintain, and to convert into a persistent form. This situation is called "AF begets AF,' with fundamentally, a reduction of refractoriness being observed. Another important work [Goette et al. 1996; Morillo et al. 1995] was on a canine model of rapid atrial stimulation for six weeks with a final development of sustained AF. Refractoriness was shortened and dispersed, and a delay in intra-atrial conduction was observed. In a goat model, repeating the four-week period of stimulation, with seven days of rest in sinus rhythm [Todd et al. 2004] , allowed refractoriness to return to normality. It was observed that for every period of stimulation, it turned out to be easier to induce AF than at the beginning of the study. This phenomenon demonstrated the presence of other remodeling factors in addition to refractoriness, which persisted beyond seven days of rest in sinus rhythm. In a dog model, Chen et al. [2001] showed modifications in the cardiomyocytes of pulmonary veins with automatic activity, which shortened its action potential (AP), increased its chronotropism, and showed an increase in the incidence of after potentials in comparison with the control group.
An induction of congestive heart failure (CHF) in a dog model [Li et al. 1999 ] demonstrated a substantial increase of heterogeneity in intra-atrial conduction. In humans with CHF, an electrophysiological study (EPS) [Vohra et al. 2003 ] demonstrated an increase of refractoriness and of conduction alterations, as shown by regional delays. These patients had a greater facility for AF induction than the group of patients with no CHF.
In atrial myocytes obtained during cardiac surgery from patients with or without chronic AF [Bosch et al. 1999 ], a reduction of their AP was observed in fibrillated patients. Similarly, Franz et al. [1997] observed that in patients with AF or chronic atrial flutter, at a few minutes post cardio-version, AP was significantly shortened compared to the nonfibrillated group.
Neurovegetative alterations also contribute to electrical remodeling, which can act as triggers or AF maintainers. Vagal stimulation is known to shorten refractoriness.
To summarize the changes in ionic channels observed in AF result in the myocyte AP to be shortened by the loss of the plateau (phase 2), with ICaL ionic flow being strongly reduced, at the same time by this loss Van Wagoner, 2004; Van Wagoner et al. 1999; Yue et al. 1997 ]. Ca++ cytosolic overload might cause these changes in situations of tachycardia and/or injury and oxidation [Hove-Madsen et al. 2004] . Also, tachycardia provokes an overload of calcium in the myocyte, which induces a functional inactivation and a genetic down-regulation of the IcaL, thus preventing a possible lethal overload of Ca++ at the expense of a shortening of the AP duration and consequently, of the refractory period (RP). Furthermore, during tachycardia, AF, or in other ischemic situations, atrium can reach a negative metabolic balance with a decrease of the reserves of energy and alterations in the oxidative state. A fall in PO 2 reversibility inhibits the subunit alfa1c of IcaL. Ischemic atrium also activates the K+ channels regulated by ATP, thereby shortening the AP. In 1982, White demonstrated that in acute AF, the rise in O 2 consumption is greater than the increase in perfusion [White et al. 1982] . The increase in the cytosolic Ca++ activates the Na+/Ca++ interchange pump mechanism in order to extract Ca++, thus generating an inflow of Na+ and a local depolarization of the membrane. If this Review happens in several places, it is possible to induce a global depolarization of the membrane, and consequently an after-potential, thereby facilitating a pro-arrhythmic state. In patients without cardiopathy who underwent induction of AF, it was demonstrated that administration of verapamil prevented electrical remodeling being produced by fibrillation and therefore diminished AF re-induction [Wijffels et al. 1997 ]. Consequently, cytosolic Ca++ overload, due to either metabolic alterations or tachycardia, provokes the appearance of after-potentials and the shortening of the AP and the RP, thus remodeling the tissue to induce and/or to maintain AF.
Although these changes are factors involved in AF physiopathogenia, it does not imply that its presence always induces fibrillation, as it is present in other situations of cardiopathy with nonfibrillated hearts.
With AF, there is a rapid and reversible electrical remodeling, at least at the beginning, with structural changes appearing over time. When alterations in the structure are detected, changes appear in the intra-atrial conduction [Morillo et al. 1995] . In the goat model, an atrial enlargement was induced -with a parallel major facility of AF induction -together with disarray in the orientation of fibers and the focal hypertrophy of myocytes, also an increased number and size of mytocondrias, and the disruption of Sarcoplasmic Reticulum (SR) and the consequent ionic alterations that this can create [Ausma et al. 1997 ]. Alterations to the 'unions gap' also occur [Velden HM et Goes der et al. 2000; Hagendorff et al. 1999 ].
How reversible are structural changes in AF? Three groups of goats were compared to investigate this: goats with 4 months in AF, a group after 2 and 4 months post-AF, and a control group [Ausma et al. 2003 ]: It was found that (a) there was an entire reversion of electrophysiological changes, except for the persistence of a major duration -although nonsustained -of induced AF episodes, (b) structural remodeling persisted, although in regression and towards normalization.
On analysis of the effect of CHF in atrium histology, the canine model of CHF [Li et al. 1999] showed an extensive interstitial fibrosis, cellular hypertrophy, disruption of sarcomeres, and loss of myofibrilles. These ultra-structural changes were similar to those observed in dogs with mitral insufficiency [Boyden et al. 1982] and also in cats with cardiomyopathy [Boyden et al. 1984] . In all of these models AF was developed. For a similar CHF model, atrial and ventricular tissue was examined [Nessrine et al. 2004] , with the provoked CHF being associated with more fibrosis in the left atria than in the left ventricle, and a parallel increase occurring in the atrial tissue concentration of Angiotensin II (AgII), of MAPKs ("mitogen-activated protein kinase") and also a significant increase in the 25 kDa activated form of TGF-beta 1, an important profibrotic mediator. There was also apoptosis, infiltration of inflammatory cells, and cellular death. All these changes were earlier and more significant in the atrium than in the ventricle. The reversion of CHF is not able to revert completely the already installed fibrosis , Shinagawa et al. 2002a ]. An analysis of transgenic mice [Rubart-von der Lohe et al. 2004] with atrial fibrosis caused by over-expression of TGF-Beta1 showed an increased vulnerability for AF. Furthermore, interstitial fibrosis makes the tissue more heterogeneous, changing from uniform to nonuniform atrial conduction. These alterations in micro-and macro-architecture and also in anisotropic properties can cause propagation of nonhomogeneous and discontinuous activation. An increase in the inducibility of AF is observed in aged animals [Hayashi et al. 2003] and in mitral insufficiency models [Verheule et al. 2003 ]. Similarly, theoretical models have implied atrial interstitial fibrosis as a substratum of AF [Spach and Boineau, 1997 ]. Finally, fibrosis has been also observed in patients with isolated AF [Frustaci et al. 1997 ].
Renin-angiotensin system
Circulating RAS is responsible for a rapid control of circulatory volume homeostasis. Tissue RAS, by means of autocrine and paracrine effects, has a slow and long-term regulation and is responsible for the structural modifications attributed to AgII-remodeling and hypertrophy -for example, in cardiac myocytes and fibroblasts, all the components of RAS are found. Angiotensin Converter Enzyme (ACE), chymases, and other enzymes promote the step from Angiotensin I to Ag II.
Angiotensin II type 1 receptors (AT1-R) mediate most of Ag II "chronic' cardiovascular actions [Matsubara, 1998 ]. Among other effects that can be enumerated are: an increase in the endothelial production of endothelin and PAI 1, the induction of fibroblast transformation into myofibroblasts and cardiomyocyte hypertrophy [Sadoshima and Izumo, 1993] , pro-inflammatory effects, and inducing the production of reactive oxygen species, inflammatory cytokines, and molecules of adherence [Brasier et al. 2002] . In agreement with these remarks, the blockade of the aforementioned AgII receptor significantly reduces the levels of multiple inflammatory markers (C-reactive protein, TNF-alfa, IL-6, and monocyte chemotactic protein-1) in hypertensive patients [Lopez et al. 2001] . It is necessary to emphasize its participation in the synthesis and deposit of collagen in the extra cellular matrix. Cardiac fibroblasts respond to the AgII stimulus, thereby increasing the expression of proteins of that matrix, such as collagen, fibronectin, and integrins. In rats, exposition of cultivated fibroblasts to AgII or aldosterone also promotes collagen synthesis. AgII also reduces collagenase activity [Brilla et al. 1994 ]. In transgenic mice, over-expression of AT1-R results in cardiac hypertrophy due to interstitial fibrosis, and death from progressive heart failure [Paradis et al. 2000 ].
Angiotensin II type 2 receptors (AT2-R) strongly express themselves during fetal life, but poorly in the adult cardiovascular system. In myocytes, they are able to antagonize the positive chronotropic and prohypertrophic action exerted by AT1-R. Stimulation of AT2-R also inhibits the proliferative processes [Matsubara, 1998] , with these receptors also producing vasodilatation via bradicinine, NO and GMPc actions. AT2-R expression can be modulated by the pathological states associated with remodeling or tissue inflamation. In hearts with failure, or in intimal neoformation postvascular injury, these AT2-R receptors re-express themselves in interstitial or neointimal proliferative cells and exert an inhibitory effect on the signals mediated by AT1R, resulting in a decrease of remodeling.
Concerning RAS, we can say that it is involved in the myocardial fibrosis of hypertensive cardiopathy [Brilla et al. 1990 ], congestive heart failure [Weber et al. 1993; Weber and Brilla, 1991] , myocardial infarction [Hanatani et al. 1995] , and cardiomyopathy [Urata et al. 1993 ].
The works of Boldt and Goette could help to link these concepts with the ones analyzed earlier. These studies were performed on patients who underwent surgery due to isolated, paroxistic, or chronic AF, mitral valve disease with AF, and also in coronary patients with sinus rhythm (control group) [Boldt et al. 2003 ]. Samples of both atria were studied in order to measure the protein levels of AT1-R and AT2-R. In the left atria, the AT1-R levels were increased for all AF forms in comparison to the control group, without significant changes occurring in AT2-R. The increase in AT1-R was similar in patients with paroxistic and chronic AF, with or without mitral valvulopathy. On the other hand, patients with valvular disease but with no AF did not present a rise in the AT1-R levels, implying that it is necessary to sum up the remodeling factors in order to reach AF: AT1-R might also be involved in the AF pathogenesis. There were no changes either in AT1-R or in AT2-R levels, in the right-atria of fibrillated patients.
These findings should be analyzed together with the work of Goette et al. [2000a,b] , which showed a decrease in AT1-R and an increase in AT2-R in comparison with nonfibrillated patients in the atrial tissue of surgical fibrillated patients. Are these differences due to the left atrium being the 'source' of AF? As an increment of AT1-R induces fibrosis, it is possible that the increase of AT2-R in the right atria is a signal of a counter-regulation against this fibrosis. There is an increased expression of ACE and extracellular-regulatory-kinases ("ERKs") in fibrillated patients that may contribute to development of fibrosis [Goette et al. 2000a,b] .
We now know that aldosterone (increased production due to RAS activity) also has a cardiac origin, and that it plays an important role in the processes of cicatrization and fibrosis [Weber et al. 1993; Weber and Shines, 1991] . It can also produce direct electrophysiological changes [Tillmann et al. 2002] . AF increases seric aldosterone levels, with return to sinus rhythm bringing them back to normality [Milliez et al. 2005] .
Another system to consider in the regulation of cardiac fibrosis is the endogenous metalloproteinase of the extracellular matrix system, and zinc-dependent enzymes, which are capable of degrading most of the matrix components [Sivasubramanian et al. 2001 ]. These products of degradation serve as a stimulus to collagen synthesis, thus increasing the deposition of poorly structured fibrotic tissue. These enzymes Review have been used recently in atrial remodeling in congestive heart failure [Mukherjee et al. 2006] and also in patients with AF [Gramley et al. 2007 ].
Blockage of the renin-angiotensin system and atrial fibrillation
Considering the 'pro-fibrillatory' atrial remodeling effects induced by RAS, we assume that its blockade could have "antifibrillatory' effects.
Potential mechanisms could be:
(1) Direct modulation of ionic channels (2) Hemodynamic improvement (3) Reduction of atrial stretching (4) Suppression of atrial fibrosis development
The direct electrophysiological effects of AgII are unclear. It has been observed that it could affect ionic channels, action potentials, and conduction, with its over-expression possibly facilitating re-entries. However, there are no direct measures in human electrophysiology. AgII increases atrial pressure and induces 'stretching,' which in turn reduces the refractory period and deteriorates the intra-atrial conduction. It has been postulated that ACE inhibitors (ACEI) and AgII receptors antagonists (ARAII) modulating K+ and Ca++ channels, can reduce the pernicious remodeling effects of RAS [Ehrlich et al. 2006 ]. Nevertheless, the role of RAS has not been clarified in acute atrial remodeling in animal models [Shinagawa et al. 2002a,b; Nakashima et al. 2000; Willems et al. 2001] . In one study on humans, 12 patients were observed during supraventricular tachycardia ablations [Kistler et al. 2005] . Also, atrial electrophysiology, with autonomic blockade, was studied during baseline and during intravenous infusion of AgII, dripping to two different doses, which were sufficient to increase by up to seven times the AgII level in plasma. Levels were significantly higher than those reached in heart failure, and provoked a significant increase in blood pressure. However, there were no modifications in atrial refractoriness, in conduction, or in AF induction. These and other findings in humans, make it impossible to be able to affirm that that AgII plays a significant role in acute remodeling. Kumagai et al. [2003] evaluated the effect of ARAII on chronic remodeling in a canine model of AF, by performing a weekly EPS. At 5 weeks in the group treated with Candesartan, although there was no difference in the grade of reduction of the refractory periods compared to the control group, the average duration of induced AF was shorter, as also was the time of intra-auricular conduction. This treated group had significantly less fibrosis in the right atrium appendix. Therefore, structural remodeling, and consequently electrical remodeling, was prevented by RAS blockade. Li et al. [2001] analyzed changes in AgII and in one of its mediators -important in the stimulation of fibroblasts -MAPK (associated mitogen-activated protein kinase) in a dog model of congestive heart failure-induced remodeling. Enalapril attenuated changes in AT1-R, decreased the duration of induced AF, and reduced alterations in the heterogeneous atrial conduction and fibrosis. The hydralazine-isosorbide association did not have these 'antiarrhythmogenic' effects: with the hemodynamic effect alone, despite reducing atrial stretching, not being sufficient. Another mechanism of antifibrotic action of RAS blockade is the inhibition of the expression of matrix metalloproteinase. In cell culture, ramipril has been demonstrated to reduce the collagen deposition by more than 50% [Ahimastos et al. 2005] .
In recent years, clinical evidence has appeared to support the beneficial actions of ACEI and ARAII on the remodeling. A group of patients with chronic AF -with more than three months of persistence -received amiodarone or amiodarone plus enalapril four weeks before an electrical cardioversion [Ueng et al. 2003 ]. The group on enalapril showed a higher probability of remaining in sinus rhythm at four weeks (84.3% vs 61.3%, P = 0.002) and at a median followup period of 270 days (74.3% vs 57.3%, P = 0.021). Yin et al. [2006] compared the efficacy, in the long term, of amiodarona at a low dose (200 mg) alone, or combined with losartan or perindopril, in the prevention of the recurrence of paroxysms in isolated AF in 177 patients after 24 months of follow-up. AF recurrence was found to be 41, 19, and 24%, respectively (P = 0.02). The Kaplan-Meier analysis demonstrated a significant reduction of AF with losartan (P = 0.006, log-rank test), and also with perindopril (P = 0.04, log-rank test), when they were compared with amiodarone alone. Coincidentally, in the losartan and perindopril groups, the atrial diameter was significantly less than in the amiodarone group. In a retrospective analysis of the AFFIRM study [Murray et al. 2004] , on 732 randomized patients to rhythm control, patients treated with ACEI -in the sub-group of congestive heart failure patients -presented a minor AF recurrence. A LIFE Study [Wachtell et al. 2005] included 9,193 hypertensive patients with left ventricular hypertrophy, who were randomized to losartan versus atenolol and followed for 4.8 ± 1.0 years. New-onset AF occurred in 6.8 per 1,000 person-years in the losartan group versus 10.1 in the atenolol group (relative risk = 0.67, 95% confidence interval 0.55-0.83, P <0.001) despite similar effects on blood pressure. The patients with new-onset AF presented 2-, 3-, and 4-fold cardiovascular events, stroke, and hospitalization due to heart failure, respectively. In fibrillated patients treated with losartan, the incidence of these events was lower than in those patients treated with atenolol. Of the 391 patients with chronic heart failure from the Montreal Heart Institute included in the SOLVD -Studies of Left Ventricular Dysfunction -randomized to enalapril or placebo, 374 were in sinus rhythm at the time of inclusion [Vermes et al. 2003 ]. In a 2.9 ± 1.0 years follow-up, 54 patients had AF: 10 patients (5.4%) were in the enalapril group and 45 (24%) in the placebo group (P <0.0001). By Cox multivariate analysis, enalapril was the most powerful predictor for risk reduction of AF (hazard ratio, 0.22; 95% CI, 0.11-0.44; P <0.0001). The TRACE Study [Pedersen et al. 1999] showed, in patients with ventricular dysfunction postacute myocardial infarction, a significant decrease in the incidence of AF in patients treated with Trandolapril. Finally, a meta analysis of studies that collected data on AF development and ACEIs-ARBs, included 11 studies, with 56,308 patients. Of these studies, four were on congestive heart failure patients, three on hypertensive patients, two on postcardioversion patients for AF and two on postacute myocardial infarction patients [Healey et al. 2005] . Overall, ACEIs and ARAII reduced the incidence -relative risk -of AF by 28% (95% confidence interval 15% to 40%, P = 0.0002). This reduction was similar between the two classes of drugs. The antiarrhythmic effect was higher in patients with congestive heart failure (RRR = 44%, P = 0.007). For patients with hypertension, the reduction was not significant, but showed a positive effect in hypertensive patients with left ventricular hypertrophy. In postcardioversion patients, there appeared to be a positive effect (48% RRR), but the analysis produced a too wide confidence limit (95% CI 21-65%). On the same physiopathogenic chain, it is necessary to bear in mind that antagonizing aldosterone decreases ventricular fibrosis in hypertensive patients, and this might be useful for preventing atrial fibrosis [Lopez et al. 2001] , and therefore AF.
Summary
It is clear the arrytmogenic effect of some states of hemodynamic overloads, different cardiopathies, and even some tachyarrhythmia, facilitate the new onset and persistence of AF. The dangerous effects of the over-activity of RAS were also demonstrated, and that its blockade, through ACEI, ARAII, and perhaps also the new antirrenin drugs, can help to a regression of the arrytmogenic remodeling state. Some current studies are attempting to shed more light on the subject, and the scientific community is waiting for a clinical mega trial that could clarify the real value of RAS blockade in arrhythmias.
